VIENNALAB - Established innovations in diagnostics

Statins are widely prescribed as treatment for hypercholesterolemia but can cause severe side effects. The SLCO1B1 c.521T>C RealFast™ Assay identifies a genetic variant responsible for simvastatin induced myopathy.

Response to statin therapy

  • The c.521T>C variant of the solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene affects the hepatic uptake and metabolism of statins.
  • Simvastatin is a widely prescribed statin for lowering LDL cholesterol levels but may cause dose-dependent adverse events.
  • Patients carrying the c.521C allele have a higher risk of simvastatin induced myopathy and rhabdomyolysis.
  • Adjustment of simvastatin dose according to the SLCO1B1 c.521T>C genotype is recommended by the Clinical Pharmacogenetic Implementation Consortium (CPIC).

Product Details

SLCO1B1 c.521T>C RealFast™ Assay ref7-210 7-213